These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19434735)

  • 41. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
    Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
    Kamm MA; Hanauer SB; Panaccione R; Colombel JF; Sandborn WJ; Pollack PF; Zhou Q; Robinson AM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):306-17. PubMed ID: 21645018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.
    Burmester GR; Mease P; Dijkmans BA; Gordon K; Lovell D; Panaccione R; Perez J; Pangan AL
    Ann Rheum Dis; 2009 Dec; 68(12):1863-9. PubMed ID: 19147611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.
    Osterman MT; Sandborn WJ; Colombel JF; Peyrin-Biroulet L; Robinson AM; Zhou Q; Lewis JD
    Am J Gastroenterol; 2016 Dec; 111(12):1806-1815. PubMed ID: 27670599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
    Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
    Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience.
    Fiorino G; Szabò H; Fries W; Malesci A; Peyrin-Biroulet L; Danese S
    Curr Med Chem; 2011; 18(8):1230-8. PubMed ID: 21291363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
    Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
    Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adalimumab: in Crohn's disease.
    Plosker GL; Lyseng-Williamson KA
    BioDrugs; 2007; 21(2):125-32; discussion 133-4. PubMed ID: 17402796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
    Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
    Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term durability of response to adalimumab in Crohn's disease.
    Chaparro M; Panés J; García V; Merino O; Nos P; Domènech E; Peñalva M; García-Planella E; Esteve M; Hinojosa J; Andreu M; Muñoz F; Gutiérrez A; Mendoza JL; Barrio J; Barreiro-de M; Vera I; Vilar P; Cabriada JL; Montoro MA; Aldeguer X; Saro C; Gisbert JP
    Inflamm Bowel Dis; 2012 Apr; 18(4):685-90. PubMed ID: 21618353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.